Form 4 for STLN Starling Oncology, Inc.
Accepted 2026-04-16 19:27:23 ET · period of report 2026-04-14 · accession 0001079973-26-000499 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MT | 2026-04-16 19:27 | 2026-04-14+ | STLN | Kaushal Mohit | Dir | S - Sale | $3.50 | -95.7K | 172.6K | -36% | -$335.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-04-14 | S | D | 57,286 | $3.50 | 211,016 | D | — | — | (F1) Represents shares sold pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 16, 2025. (F2) Price of $3.5017 was the volume weighted average selling price of all sales by the reporting person on April 14, 2026 within a one-dollar range. Actual prices ranged from $3.5000 to $3.5300. The reporting person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price. |
| 2 | Common | Common Stock | 2026-04-16 | S | D | 38,433 | $3.50 | 172,583 | D | — | — | (F1) Represents shares sold pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 16, 2025. (F3) Price of $3.5005 was the volume weighted average selling price of all sales by the reporting person on April 16, 2026 within a one-dollar range. Actual prices ranged from $3.5000 to $3.5050. The reporting person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price. |